Hepatic lipase (HL) plays a key role in the metabolism of plasma lipoproteins, and its level of activity requires tight regulation, given the association of both low and high levels with atherosclerosis and coronary artery disease. However, little is known about the factors responsible for HL expression. Here, we report that the human hepatic lipase gene (LIPC) promoter is regulated by hepatocyte nuclear factor 4a (HNF4a), peroxisome proliferator-activated receptor g coactivator-1a (PGC-1a), apolipoprotein A-I regulatory protein-1 (ARP-1), and hepatocyte nuclear factor 1a (HNF1a). Reporter analysis showed that HNF4a directly regulates the LIPC promoter via two newly identified direct repeat elements, DR1 and DR4. PGC-1a is capable of stimulating the HNF4a-dependent transactivation of the LIPC promoter. ARP-1 displaces HNF4a from the DR1 site and blocks its ability to activate the LIPC promoter. Induction by HNF1a requires the HNF1 binding site and upon cotransfection with HNF4a leads to an additive effect. In addition, the in vivo relevance of HNF4a in LIPC expression is shown by the ability of the HNF4a antagonist Medica 16 to repress endogenous LIPC mRNA expression. Furthermore, disruption of Hnf4a in mice prevents the expression of HL mRNA in liver. The overall effect these transcription factors have on HL expression will ultimately depend on the interplay between these various factors and their relative intracellular concentrations.-Rufibach, L. E., S. A. Duncan, M. Battle, and S. S. Deeb. Hepatic lipase (HL) is a 477 amino acid glycoprotein that plays an important role in lipoprotein metabolism. The majority of HL is synthesized and secreted by the liver, where it has been shown to act as both a lipase and a ligand. As a lipase, it catalyzes the hydrolysis of triglycerides and phospholipids of intermediate density lipoprotein remnants, large buoyant LDLs, and HDLs to form smaller, denser lipoprotein particles (1, 2). Studies in humans have shown an association between high HL activity and increased plasma concentrations of small, dense LDL and HDL particles, one of the major risk factors for coronary artery disease (3-5). As a ligand, HL contributes to the process of reverse cholesterol transport by participating with surface proteoglycans and the low density lipoprotein receptor like-protein in promoting hepatic uptake of lipoproteins, including remnant LDL and HDL particles (6-8), thus mediating the hepatic uptake of HDL-cholesteryl esters (9). The observed association of low HL activity with coronary artery disease might be attributable to decreased HL-enhanced remnant uptake by the liver (10). Together, these data show that HL is an important enzyme in lipid metabolism that must be highly regulated, because both low and high levels of HL activity appear associated with dyslipidemia.The expression level of hepatic lipase activity varies widely in normal individuals (5-to 8-fold) and is influenced by genetic variation, obesity, gender, intracellular cholesterol, and lipid-lowering therapy (11). H...